BMC Cancer journal publishes encouraging HER-Vaxx research
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Imugene progresses mimotope platform
- Response to ASX Aware Query
- Acquisition of immuno-oncology technology
- Leslie Chong Appointed Chief Executive Officer
- Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
Later from Imugene
- Intellectual Property Strengthened Around Lead Clinical Drug
- Half Year Report and Accounts
- $1.35 million Options Underwritten
- IMU Raises $3.0m from Options Plan
- Appendix 4C - quarterly and Commentry Q3
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene